论文部分内容阅读
目的系统评价沙美特罗/替卡松联用噻托溴铵治疗中、重度慢性阻塞性肺病的临床疗效。方法计算机检索Pub Med、Ovid、CNKI、VIP、CBM、万方等数据库内有关沙美特罗/替卡松联用噻托溴铵,与单用沙美特罗/替卡松或单用噻托溴铵治疗中、重度慢性阻塞性肺病的随机对照研究,检索年限均为2000年1月至2015年5月,对纳入研究进行文献质量评价,采用Rev Man 5.2统计软件对同质性结果进行合并分析。结果共纳入文献15篇,其中13篇为中文,2篇为英文,合计2847例患者。Meta分析显示,联合用药对中、重度慢性阻塞性肺病患者肺功能、临床症状和生活质量的改善均优于单用沙美特罗/替卡松,除尚不能确定联合用药在降低PaCO_2优于单用噻托溴铵外,在肺功能、PaO_2和生活质量的改善也优于单用噻托溴铵。联合用药未增加不良反应的发生率,未加重不良反应的损害程度。结论沙美特罗/替卡松联用噻托溴铵治疗中、重度慢性阻塞性肺病是安全有效的,值得进一步推广。
Objective To systematically evaluate the clinical efficacy of salmeterol / ticarcone in combination with tiotropium in the treatment of moderate and severe chronic obstructive pulmonary disease. Methods Six hundred and sixty-eight patients with salmeterol / ticacustine combined with salmeterol / ticlopromide alone or with tiotropium bromide alone or in combination with salmeterol / ticagrelor alone in Pub Med, Ovid, CNKI, VIP, CBM, A randomized, controlled trial of ammonium for the treatment of moderate-to-severe chronic obstructive pulmonary disease from January 2000 to May 2015 was conducted to evaluate the quality of literature included in the study and the homogeneity results were analyzed using RevMan 5.2 statistical software . Results A total of 15 articles were included, of which 13 were Chinese and 2 were English, with a total of 2847 patients. Meta-analysis showed that combination therapy improved pulmonary function, clinical symptoms and quality of life in patients with moderate or severe chronic obstructive pulmonary disease over salmeterol / ticacasone alone, except that combination therapy was less effective than single In addition to tiotropium bromide, improvements in lung function, PaO 2, and quality of life were also superior to tiotropium alone. The combination did not increase the incidence of adverse reactions, did not increase the extent of adverse reactions. Conclusions Salmeterol / Ticcassone combined with tiotropium in the treatment of moderate and severe chronic obstructive pulmonary disease is safe and effective, which is worth further promotion.